Information Provided By:
Fly News Breaks for September 13, 2018
MNTA
Sep 13, 2018 | 16:24 EDT
Stifel analyst Derek Archila assumed Momenta with a Buy rating and a price target of $40, saying the stock offers an investment in an "exciting biotech company that has a pipeline with demonstrated proof-of-mechanism". The analyst expects sentiment on Momenta to shift as it "completes its strategic review, ideally sheds costs/potentially monetizes its legacy businesses, and narrows its focus on its proprietary pipeline M281 and M254.
News For MNTA From the Last 2 Days
There are no results for your query MNTA